Phase 3 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have voluntarily agreed to take part and have signed a written informed consent form.
- People aged 18 years or older at the time of signing the consent form.
- People whose general health and ability to carry out daily activities is rated as fully active or restricted only in physically strenuous activity (an ECOG score of 0 or 1).
- People with a life expectancy of at least 3 months.
- People who have been confirmed through tissue or cell testing to have locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC), where surgery to fully remove the cancer is not possible and intensive combined radiation and chemotherapy treatment is also not suitable.
- People who have not previously received any systemic (whole-body) treatment for advanced or metastatic NSCLC.
- People whose cancer tests show a PD-L1 score of less than 1% (a measure of a specific protein on cancer cells) (confirm with trial site).
- People whose cancer does not carry specific gene changes known as EGFR sensitive mutations or ALK gene translocations.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer has been confirmed as small cell lung cancer (SCLC).
- People with NSCLC that has specific gene mutations for which approved targeted treatments already exist.
- People who currently have active cancer that has spread to the brain or spinal cord.
- People who have received radiation treatment to the lungs at a dose greater than 30 Gy within the 6 months before the first dose of the study treatment.
- People who have had another active cancer within the past 5 years, except for the lung cancer being studied or certain localised cancers that have been fully treated (confirm with trial site).
- People who are pregnant or currently breastfeeding.
- People with significant heart or blood vessel disease affecting the heart or brain.
- People with a known history of severe allergic reactions to other monoclonal antibody treatments, or a known allergy or hypersensitivity to any of the study drugs or their ingredients.
- People who have an active autoimmune disease (where the immune system attacks the body) that required systemic treatment within the past 2 years, or an autoimmune condition that may return or need planned treatment, as assessed by the treating doctor.
- People with known active tuberculosis affecting the lungs.
- People with active hepatitis B or active hepatitis C infection.
- People with a known medical history of immune deficiency, or a positive HIV test result.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jie Wang, M.D., Cancer hospital, Chinese academy of medical sciences and Peking union medical college
Phone: +86-0760-89873999
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
Overall Survival(OS); Progression-Free Survival(PFS) by investigator(INV)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.